Open access peer-reviewed chapter

Structure - Functions Relations in Small Interfering RNAs

Written By

Natalya S. Petrova, Marina A. Zenkova and Elena L. Chernolovskaya

Submitted: December 14th, 2011 Reviewed: October 1st, 2012 Published: January 9th, 2013

DOI: 10.5772/53945

From the Edited Volume

Practical Applications in Biomedical Engineering

Edited by Adriano O. Andrade, Adriano Alves Pereira, Eduardo L. M. Naves and Alcimar B. Soares

Chapter metrics overview

3,795 Chapter Downloads

View Full Metrics

1. Introduction

RNA interference is an evolutionary conserved mechanism of specific gene silencing induced by double stranded RNA homologous to the target mRNA. Small interfering RNAs (siRNAs) are widely used for the control of gene expression in molecular biology and experimental pharmacology. Currently, siRNAs are successfully used for the validation of potent drug targets for anti-cancer therapy. However, application of siRNAs as therapeutics is limited by their sensitivity to ribonucleases, poor cellular uptake and rapid size-mediated renal clearance. These challenges must be overcome to develop a successful siRNA-based drug. Many of these limitations could be resolved with the use of chemical modifications improving the siRNA properties.

This review examines recent data regarding principals of the design of siRNA for the silencing of therapeutically relevant genes. A particular focus will be made on chemical modifications and their impact on siRNA potency, nuclease resistance and duration of the silencing effect. The types of chemical modifications, their location in siRNA structure influence siRNA properties in different modes: modulation of the interaction with RNAi proteins, the thermal stability and thermoasymmetry of the duplex and the sensitivity to the degradation by ribonucleases.

Special attention will be paid to the design of siRNA for the silencing of thermodynamically unfavorable targets: mutant and chimerical genes. In this case the utilization of computer algorithms for the selection of active siRNA cannot be applied. Modification of siRNA structure aimed at the correction of the thermoasymmetry by incorporation of nucleotide substitutions, blocking incorporation of the sense strand in the RISC complex by truncation of one overhang or inactivation of the sense strand can be successfully used. Mismatches in the central part of the duplex can facilitate the cleavage and dissociation of the “passenger” (sense) strand, whereas selective chemical modification protects the non-perfect duplex from accelerated degradation.

Peptides, steroids and other hydrophobic lipid groups can be attached to siRNA, extending the siRNA circulation time and enhancing direct cellular uptake. The potential of bioconjugation of siRNA with different biogenic molecules in altering the bioavailability and distribution of siRNAs following in vivodelivery will be discussed. The combination of these approaches can lead to the development of siRNAs with therapeutic value.


2. Mechanism of RNAi

RNAi phenomenon was found during transfection of dsRNAs in C.elegans[1]and is inherent in different organisms (flies, vertebrates, higher plants [2, 3, 4]). RNAi mechanism was initially examined in details in Drosophila melanogaster, but later it was found that the mechanism is highly conservative between the organisms. There are two stages of RNAi (fig. 1): at the first stage (phase of initiation) specific ribonuclease Dicer binds to and cleaves long dsRNAs yielding short (21-23 nt) duplexes with 2-overhanged nucleotides at the 3’-ends (or siRNAs); at the second stage (effector phase) siRNAs molecules incorporate into multiprotein complex (RISC – RNA-induced silencing complex). One of siRNA strands ("passanger") undergo cleavage and dissociation from the complex upon RISC activation, the other strand ("guide") remains in the complex. Activated complex RISC* specifically binds to RNA target and cleaves it (fig. 1) [5, 6, 7, 8,9, 10]. Long dsRNAs (> 30 bp) activate the innate immune response in the mammalian cells (except for non-differentiated or low differentiated cells) resulting in non-specific RNA degradation by RNase L, activation of protein kinase PKR that inhibits translation. The expression of numerous genes, including genes encoding interferons and cytokines, alters [11, 12]. Thus, sequence-specific decrease of target mRNA level is not observed. It was found that RNAi in mammalian cells can be induced by chemically or enzymatically (in vitro) synthesized siRNAs or endogenously expressed siRNAs 19-21 bp in length. These siRNAs mimic the products of long dsRNAs processing by Dicer and can be involved directly into the effector phase of RNAi mechanism passing the phase of initiation (fig. 1) [13, 14, 15, 16, 17].

Figure 1.

Scheme of RNAi. A. Initiation phase B. Effector phase.

The selection of the "guide" strand is a key step determining the efficacy of RNAi induced by synthetic siRNAs. At the first step of RISC* assembly the intermediate complex RLC (RISC Loading Complex) consisting of Dicer, siRNA and R2D2 (D.melanogaster) or TRBP [18, 19, 20] (Homo sapiens) forms (fig. 2 A). R2D2 protein along with its human analog contains two dsRNA-binding domains and a Dicer binding domain.

Figure 2.

RISC* assembly. A. RLC-complex, consisting of Dicer, dsRNA-binding protein, R2D2 and siRNA. B. Interaction of Ago2 with RLC. C. RISC* formation.

Dicer contains dsRNA-binding domain and PAZ-domain (PIWI/Argonaute/Zwille), that has an affinity to 3’-overhangs of siRNA [21, 22]. It was detected that R2D2 preferably binds with more thermodynamic stable flank of the siRNA duplex, whereas Dicer interacts with less stable siRNA flank [20, 23, 24, 25]. The orientation of siRNA relative to the protein complex Dicer-R2D2 determines the positioning of siRNA in the complex with Ago2 (a catalytic part of RISC*) (fig. 2 B). Ago2 is a protein of Argonaute family, containing PAZ and PIWI domains. The structure of PIWI domain similar to that of RNase H determines endoribonuclease activity of PIWI [26, 27]. Ago2 cleaves the one of the siRNA strand (“passenger” strand), another strand (“guide” strand) remains into the RISC* and guides the target RNA recognition and cleavage (fig. 2 C). The structure of the complex containing siRNA and Ago2 effects the selection of the strand (sense or antisense) that incorporates into RISC*, hence, determines the efficacy of mRNA-target cleavage. Evidently, the antisense strand that is homologous to the sequence of mRNA-target has to be “guide” strand in order to cleave mRNA. Ago2 replaces the Dicer-R2D2 dimer (fig. 2 B), interacting with Dicer via PAZ domain[28] whereas the phosphate group at the 5’-end of the strand from the Dicer side (“guide” strand) interacts with PIWI domain that contains Mg2+ ion and basic amino acids.

The nucleotides located at 2 - 6 positions of the “guide” strand stabilizes the interaction between siRNA and Ago2 [29, 30, 31]. The presence of the phosphate at the 5’-end of the “guide” strand is essential for RISC* assembly [32, 33]. This orientation of siRNA with respect to catalytic PIWI-domain provides the cleavage of the complementary strand (“passenger” strand) between 9th and 10th nucleotides that facilitates the strand dissociation (fig. 2 C) [34, 35]. Ago2 and the “guide” strand are the main components of RISC* [36], however, other proteins could also interact with RISC* [10]. Thus, the difference between thermodynamic stability of the duplex termini (thermodynamic asymmetry) determines the orientation of Dicer-R2D2 dimer and as a result, the structure of Ago2-siRNA complex. Therefore, thermodynamic properties of siRNA play a key role in the strand selection [20, 23, 24, 25] providing the preferential selection of the strand with low thermodynamic stability at the 5’-end of the duplex as the “guide” strand [37, 38].

It was shown, that the perfect match between 2 - 12 nt of the “guide” strand (corresponding to one turn of dsRNA helix) and the target mRNA is essential for effective recognition and binding of RISC* with mRNA target [39]. The mechanism of RNA-target cleavage (occurs between 10th and 11th nt relative to the 5’-end of the “guide” strand [40]) and the following dissociation are similar to that of the “passenger” strand (described above). Cleaved target RNA and the “passenger” strand are degraded by ribonucleases after dissociation, whereas RISC* becomes available for acting in catalytic mode [7, 9, 17, 41]. Unlike antisense oligodeoxyribonucleotides (ODN), whose efficacy of action is determined by the efficacy of ODN hybridization with mRNA-target (fig. 3) [42], the formation of the duplex between the "guide" strand of siRNA and mRNA- target occurs due to the helicase activity of RISC* and virtually independent from the hybridization properties of the oligoribonucleotide [43]. Silencing of gene expression by siRNAs is observed at the much lower ON concentrations than in the case of antisense ODN (IC50 for siRNAs is 100 – 1000 times lower, than IC50 for antisense ODNs) [43, 44].

Another mechanism of RISC activation - “bypass” route - employs the dissociation of the siRNA strands without preliminary cleavage of the sense strand by Ago2 [35]. This type of RISC activation is inherent in miRNAs, containing unpaired bases in the central part, critical for Ago2 endoribonuclease activity (fig. 4). Moreover, the “bypass” rout was observed for siRNAs with chemically modified nucleotides surrounding the cleavage site (between 9th and 10th nt of the “passenger” strand [45]) impeding Ago2 action [34, 35, 46]. Silencing of gene expression proceeds via the arrest of mRNA translation, since RISC* binds to mRNA-target together with translation suppressor proteins (for example, helicase RCK/p54 from DEAD box family) [47]. Complex of mRNA and proteins is deposited in “P-bodies” (processing bodies - distinct foci in the cytoplasm involved in mRNA turnover) [48]. In “P-bodies” mRNA decapping followed by ribonuclease cleavage occurs. In the other cases, mRNA complexed with proteins can be deposited in “P-bodies” for a long time without degradation (fig. 4). Later, mRNAs can escape from “P-bodies” and be involved in translation machinery or can be degraded in a described above manner [10].

Figure 3.

Silencing of gene expression by antisense ODNs: A. The degradation of the duplexes: ODN / mRNA or ODN / pre-mRNA by RNase H. B. Inhibition of mRNA translation or pre-mRNA splicing by ODNs those are not RNase H substrates [43].

The “bypass” mechanism of RISC activation is less efficient than the “classical” one, since in this case RISC* does not act in a catalytic mode. The efficiency of RISC* assembly also is limited by the low rate of ATP-dependent dissociation of intact siRNA strands [35, 33, 39].

Thermodynamic stability siRNA duplex is an additional parameter determining the efficiency of RISC* assembly, hence, the efficiency of RNAi. Earlier developed algorithms for the selection of active siRNA sequences suggest selection of mRNA targets with approximately 50% GC-content. In the later studies, the percentage of G+C nucleotides in the structure of effective siRNAs varied from 30 to 50% [49, 50]. It was shown that low thermodynamic stability of the central part of the duplex (from 9th to 14th nt counting from 5’-end of the antisense strand) arising from AU-rich sequences or the presence of mismatches is a hallmark of active siRNAs [37]. The average difference between Gibbs energy of central parts of active and inactive siRNAs was found to be about 1.6 kcal/mol. Unlike thermodynamic asymmetry, unstable center of duplex is not a sufficient criteria for selection of active siRNA [37].

Structural features of mRNA-target also effects the RNAi efficacy [51, 52, 53, 54]. The availability of the mRNA sequence for binding with siRNA (the absence of the hairpins in the secondary structure or overlapping with the binding regions of regulatory factors) as well as in the case of the ribozymes and the antisense ODN [55] can influence the silencing efficacy. In order to prove this, siRNAs targeted to mRNA sequences with different binding availability were synthesized [53]. It was shown that siRNAs targeted to the region of the initiation of translation or the 3’-end of mRNA-target were inactive. Whereas siRNAs targeted to the regions forming the hairpins displayed low and average silencing activity. As expected high-performance siRNAs were those targeted to unstructured regions of mRNA [51, 52, 54].

Thus, the analysis of the secondary structure of mRNA-target and thermodynamic properties of siRNA duplex play important role in the selection of active inhibitors of gene expression.

Figure 4.

Scheme of RNAiwith the “bypass” rout of RISC* assembly (miRNA-like action). RISC* binds with mRNA-target (n isequal 1, if the antisense strand is fully complementary to mRNA) [10].


3. Chemical modifications: The influence on RNAi efficacy

Currently, the development of RNAi-based drugs is an important aim in pharmacology. The optimization of siRNAs structure is required for biomedical applications; chemical modifications could be successfully used for this purpose. Different types of chemical modifications were widely used in antisense ODNs before the discovery of RNAi [42]. The data collected in these experiments can be applied for optimization of the properties of siRNAs. There are two types of factors affecting both antisense ODNs and siRNAs efficacy: systemic factors that act on the level of the organism and intracellular factors defining the activity of the therapeutics in the cells. The first type of factors includes: i) fast (approx. 5 min) siRNA elimination from organism resulted from its hydrophobicity and size of the molecule (approx. 14 kDa) [56, 57], ii) high nuclease sensitivity of siRNA [58, 59, 60, 61, 62] and iii) inefficient or/and non-specific delivery into target cells [63]. Intracellular factors are related to RISC assembly and the efficiency of binding to and cleaving the target.

3.1. Chemical modifications of the nucleotides

3.1.1. Modifications of ribose (furanose) ring

All ribose modifications can be divided in two main groups: the modifications related to the replacement of hydrogen atoms in furanose by different groups and structural modifications of the furanose cycle. Substituents in furanose

The 2’-OH group of the ribose is the main target for modification, since this group is involved in the phosphodiester bonds cleavage by endoribonucleases via trans-etherification mechanism [64]. Thus, the modification of 2’-OH defends siRNA against ribonucleases [62]. The size of the substituent is an important characteristic determining its tolerance by RNAi machinery. The small groups (2’-O-methyl (2’-O-Me), 2’-fluoro (2’-F) etc.) (fig. 5 А) virtually do not disturb the conformation of siRNA duplex and are better tolerated than bulky groups: 2’-O-methoxyethyl (2’-O-MOE), 2’-O-allyl (2’-O-allyl) etc. The replacement of 2’-OH by electrophilic groups also stabilizes C3’-endo conformation of the ribose (fig. 6) which corresponds to A-helix geometry of the duplex obligatory for effective RNAi [58]. This sugar conformation arrange for the axial location of the substituents reducing total energy of the system and increasing the affinity to the complementary RNA target. As a result the duplex melting temperature (ΔTm) increases approximately 1 0С per modification [65].

2’-O-methyl modification is one of the widely used 2’- modifications for the enhancement of nuclease resistance of siRNA [59, 62] and impeding the induction of the interferon response in eukaryotic cells [64, 66, 67, 68, 69, 70]. Obviously, the number and location of the modified nucleotides in the duplex are crucial for the silencing. The increase of the number of modifications was shown to decrease the silencing activity of siRNAs; totally modified siRNAs frequently had no activity [58, 59, 71]. However, in a number of experiments the activity of siRNA with the totally modified sense strand was compatible with that of unmodified analog[72, 73]. This can be related to functional unequivalence of siRNA strands [74, 75]. The introduction of 2 - 4 2’-О-Me modifications in the both strands of siRNA is well tolerated. Moreover, in the case of selective modification of the nuclease-sensitive sites within siRNA the increase of the duplex nuclease resistance and prolonged silencing were detected [59].

The C3’-endoconformation could be stabilized by introduction of 2’-F-modified nucleotides in siRNA (fig. 5 A). Since fluorine atom is more electronegative than oxygen atom, the increase of the binding affinity between siRNA strands and target RNA (ΔTm 2 – 4 0С per modification) is observed [65]. Remarkably, the silencing activity of 2’-F-modified siRNAs virtually does not depend on the number of modifications in contrast to 2’-O-Me-modified siRNAs. The silencing activity of siRNAs with 2’-F-modifications in the sense and the antisense strands was compatible with that of unmodified analogs [76]. The replacement of pyrimidine nucleotides in the duplex with 2’-F-analogs was well tolerated by RNAi machinery both in vitro[46, 77, 73] and in vivo[78]. The silencing activity of siRNA containing 2’-F modifications located in the site of Ago2 cleavage and unmodified analog was similar [79], as well as long-term silencing effects in vivoof modified siRNAs and unmodified analogs [78]. It should be noted that epimers of 2’-F-nucleotides (2’-fluoro-β-D-arabinonucleotides, FANA (fig. 5 A)) with DNA-like C2’-endo-conformation of furanose cycle [80] (fig. 7) introduced in siRNA structure also improve the nuclease resistance of the duplex. It was found that partial modification of both strands with FANA or total modification with FANA of the sense strand of siRNAs ensure the A-geometry helix [81] and effective RNAi. These modifications were shown to alter the duplex thermodynamic stability insignificantly [76].

Figure 5.

Analogs of nucleotides and nucleosides used for siRNA modification. A. Substituents in furanose. B. Structural modifications of furanose cycle. C. Backbone modifications. “B” – base (А– C). D. Nucleobase modifications. “R” – ribose residue.

Figure 6.

C3’-endoconformation of the ribose with the 2’-substituent. R – electron-acceptor group.

Figure 7.

C2’-endo(DNA-like) conformation of ribose with the substituent (R) in 2’-position.

On the contrary, the replacement of ribonucleotides of siRNAs with deoxyribonucleotides characterized by C2’-endo-conformation of the furanose cycle (fig. 5 A) reduces their affinity to mRNA-target (ΔTm -0.5 0С per modification) (fig. 7) [65]. Mainly, deoxyribonucleotides are used for the defense of siRNA overhangs from exonucleases [13, 59]. However, the modification of the other duplex regions does not impede effective RNAi [40, 82]. The introduction of deoxyribonucleotides in the duplex region responsible for the recognition of the target mRNA, so called "seed" region (about 8 nt. from the 5’-end of the antisense strand [29]) results in the increase of siRNA specificity since lesser stability of DNA/RNA hybrids as compared with RNA duplex [82]. siRNAs with the totally modified antisense or sense strands had no activity regardless of preferable for RNAi A-helix geometry of the duplexes [32].

Introduction of the bulky groups in the 2’-position of the furanose causes the conformational disturbance of the siRNA duplexes resulting in the decrease of siRNA silencing activity [76]. However, the modification of duplex termini and overhangs with 2’-О-methoxyethyl (2’-O-MOE) or 2’-O-allyl groups (fig. 5 A) was tolerant [46, 83, 84]. The random replacement of 2’-OH in the both strands of the siRNA (up to 70 %) by 2,4-dinitrophenyl ethers (2’-O-DNP) (fig. 5 A) causes the increase of the silencing activity. Since the thermodynamic stability of the modified duplex was comparable with that of unmodified duplex [85] (that indicates the similar hybridization properties [86]), the observed effect may be related to the increase of the nuclease resistance and cellular uptake of the modified siRNA [85, 86, 87]. In order to increase the nuclease resistance of the siRNA duplexes, other chemical modifications - 2’-aminoethoxymethyl (2’-AEM), 2’-aminopropoxymethyl (2’-APM), 2’-aminoethyl (2’-EA), 2’-cyanoethyl (2’-СE), 2’-guanidinoethyl (2’-GE) etc.- may be used (fig. 5 А). It was shown that totally modified siRNAs were inactive, whereas the silencing activity of the partially modified siRNAs depends on the location of the modifications in the duplex structure [88].

Introduction of the modifications at the 4’-position of the furanose results in the slight increase of the RNA-duplex termostability (ΔTm 1 0С per modification) [89, 90]. Usually the 4’-thio (4’-S) ribonucleosides (fig. 5 А) are used for modification of siRNA, especially, at the termini [91, 92, 93]. The replacement of the several ribonucleotides at the 5’-end of the antisense strand [91] or four ribonucleotides at the sense strand termini and at the 3’-end of the antisense strand [93] by 4’-S- analogs only slightly decrease the silencing activity of siRNAs, whereas the modification of the central part of the duplex significant inhibits RNAi [91, 92]. The introduction of the 4’-S-modifications in siRNA structure increases nuclease resistance of the duplex and improves the pharmacokinetics of siRNA. Unfortunately, this modification simultaneously increases the binding of siRNAs with blood serum components and increases their cytotoxicity [65]. Structural modifications of the furanose ring

This type of modifications includes bicyclic derivatives of the nucleotides (LNA, ENA, CLNA, CENA, AENA et al.), acyclic nucleotides (UNA, PNA) or nucleotides containing pyranose ring (ANA, HNA) instead of ribose (fig. 5 B). LNA and ENA (2'-О,4'-С-methylene- and 2'-О,4'-С-ethylene bicyclic nucleotide analogs are the frequently used bicyclic derivatives which provide the significant increase of the duplex thermostability (ΔTm up to 10 0С per modification) [94, 95]. The ribose in LNA and ENA is fixed in C3’-endo-conformation (fig. 6) due to the methylene or ethylene “bridge” between 2’- and 4’-positions, respectively.

Experimental data on the activity of LNA- and ENA-modified siRNAs are contradictory. In some cases modifications of the 5’- and/or 3’-ends of the both siRNA strands were well tolerant [65, 96, 97, 98], whereas in the other studies ENA-analogs at the 3’-end of the sense strand of siRNAs reduced or abolished the silencing activity [74]. The difference in activity may be connected with the difference in the thermodynamic asymmetry of the modified siRNA [37, 38]. The replacement of the several ribonucleotides with LNA in the antisense strand was shown to be well tolerant [71, 96], whereas extensive modification was tolerant only in the case of sisiRNA with segmented sense strand [99] (see section 1.3.5).

The thermodynamic stability and nuclease resistance of the siRNA could be increased by introduction of HNA and ANA nucleotides with pyranose ring (hexitol nucleic acid and altritol nucleic acid, respectively (fig. 5 B)) instead of ribose [100, 101]. The modified duplex contaning these analogs adopts the A-helix geometry [100], however, the location of the ANA- or HNA-analogs in siRNA structure is critical for silencing activity. Remarkably, the introduction of the ANA- or HNA-analogs at the 3’-termini of one or both strands maintain or increase the silencing activity [102, 103]. The presence of ANA-analogs at the 5’-end of the antisense strand substantially decreased the siRNA activity. It was suggested that modifications at the 5’-end of the antisense strand impede the action of cellular kinases due to steric obstacles [103]. The decrease of the phosphorylation efficacy of the 5’-terminal nucleotide of the antisense strand is critical for efficient interaction of siRNA with Ago2 PIWI domain followed by mRNA-target cleavage [32, 33]. siRNAs with HNA or ANA-analogs of nucleotides in the central part of the sense strand display the effective gene silencing, whereas, similar modifications of the antisense strand substantialy decreased the siRNA activity [88, 103].

In contrast to siRNA duplex stabilizing modifications, the presence of acyclic nucleotide analogs (UNA) (fig. 5 B) in the siRNA increase the conformational flexibility of the duplex and decrease its thermodynamic stability (ΔTm -5 to-8 °С per modification). The location of the UNA-analogs in siRNA was shown to play a key role, since one modification can result in the significant reduction or augmentation of the silencing activity of siRNA [99, 104]. It was suggested that the replacement of ribonucleotides at the 3’-end of the sense strand increases the duplex thermodynamic asymmetry and acquires antisense strand incorporation into RISC* [104, 105]. It was found experimentally that the introduction of 1 - 3 UNA nucleotides at the 3’-end of the sense strand, including the 3’-overhangs, increase to some extent the siRNA activity [106, 107]. Quite the opposite, the modification of the first and the second positions of the “guide” strand abolishes the 5’-end phosphorylation and reduce siRNA silencing activity.

Peptide nucleic acids analogs (PNA) containing N-(2-aminoethyl)-glycin polyamide backbone could be used for modification of siRNA. It was shown that in the antiparallel PNA/RNA duplex RNA adopts the right-handed helix characterized by anticonformation at the N-glycosidic bond and C3’-endo-conformation of the ribose [108], with the similar to the RNA-like A-helix geometry [58]. PNAs are stable in the human blood serum as well as in the cellular extract; they are resistant to protein kinase A and several types of peptidases [109]. It was found that the introduction of PNA-analogs in the sense and / or in the antisense strands of the duplex increase nuclease resistance of siRNA. The increase of the siRNA silencing activity was observed when modifications were introduced in the sense strand. In the other cases the activity of PNA-containing siRNA was comparable with activity of the unmodified siRNA [110]. Due to the functional inequivalence of siRNA strands the modifications in the sense strand a better tolerated than modifications in the antisense strand.

Thus, virtually all ribose modifications provide the increase of the nuclease resistance of siRNA. However, the optimization of their number and location in the duplex structure (depending on the type of modification) is required to make them tolerable in the process of RNAi.

3.1.2. Backbone modifications

This type of modifications includes the replacement of phosphate group (PO) with phosphorothioate (PS) or boranophosphonate (PB) groups, the replacement of the 3’,5’-phosphodiester bond with 2',5'-bond or the amide bond instead of the ester bond (fig. 5 C). All of these modifications increase the nuclease resistance of siRNA, however their impact on the efficacy of RNAi is varied [76]. PS-modification is known to reduce the melting temperature of the duplex and oligoribonucleotide binding affinity [71]. However, the experimental data related to the activity of PS-modified siRNAs are discrepant. The comparable silencing activity of the PS-modified siRNAs and their unmodified analogs was shown in the studies [83,111], whereas in the other studies the silencing activity of the PS-modified siRNAs was lower, than that of their unmodified analogs [58, 73, 112]. The modification of the central part of the duplex decreases siRNA activity [113]. Remarkably, siRNAs with blunt 3’-ends containing totally PS-modified one or both strands were active [73]. However, high binding affinity of the phosphorothioate analogs to serum albumin, IgG, IgM, lactoferrin and the cellular membrane receptors is disadvantageous [114]. It results in the development of toxic effects both in vitroand in vivo, even siRNAs containing alternate PS-analogs were toxic in cell cultures [83, 111]. Introduction of boranophosphonate analogs (fig. 5 C) increases nuclease resistance of the duplex as compared with PS-containing and unmodified siRNA [65] and increases RNAi efficacy. It was found that an optimal position for PB-modifications is the terminal region of the sense strand of siRNA, whereas the modification of the central part of the duplex resulted in the significant decrease of silencing activity [65]. This effect is likely connected with the inhibition of the sense strand cleavage by Ago2 during RISC* formation. The replacement of the 3’,5’- by 2’,5’-phosphodiester bond or 3’,5’-amide bond (fig. 5 C) increases the nuclease resistance of the duplex and is tolerant when located in the sense strand [115] or the 3’-overhangs of siRNA [116].

Thus, the most promising modification of the siRNA backbone is the boranophosphonate modification, since it provides the increase of the nuclease resistance of the duplex and its silencing activity and is not accompanied by the development of toxic effects. However, the price of PB-analogs limits their usage.

3.1.3. The chemical modifications of the nucleobases

In contrast to the other types of modifications, the modifications of heterocyclic bases (nucleobases) have no influence on the nuclease resistance of RNAi. Earlier it was found that the presence of modified nucleobases in the antisense ODN altered their hybridization properties [42]. It is known that the replacement of the uridine by 5-bromo- or 5-iodouridine (fig. 5 D) improves their ability to interact with adenine owing to the increase of the acidity of the imine and results in the stabilization of the base pair [117]. The replacement of the adenine by 2,6-diaminopurine results in the formation of the additional H-bond, hence, in the stabilization of the nucleotide base pair [58]. At the start, it was suggested that the introduction of these analogs in the antisense strand of siRNA will enhances its binding affinity to mRNA and increases the RNAi efficacy. Unexpectedly, the decrease of silencing activity of modified siRNA in comparison with unmodified ones was observed. This effect is possibly related with the decrease of the dissociation rate of siRNA duplex on the step of RISC* formation [58]. The replacement of uridine by 2-thiouridine (s2U) or pseudouridine (ψ) (fig. 5 D) provides the increase of the duplex thermodynamic stability due to the stabilization of the ribose in the C3’-endo-conformation (fig. 6) [118, 119]. Dihydrouridine (D) contains non-aromatic ring that does not participate in staking interactions (fig. 7) which resulted in the destabilization of siRNA [120], but one substitution with D at the 3’-end of the sense or the antisense strand does not change siRNA silencing activity. The replacement of U by Ψ and s2U at the 3’-end of the sense strand reduces the silencing activity, whereas introduction of the same modification at the 3’-end of the antisense strand creates favorable thermodynamic asymmetry and provides siRNAs with higher activities than the parent siRNA. Thus, these modifications could be applied for the design of thermoasymmetric siRNAs [120] (see section 3.3).

3.2. Chemical modification of siRNA termini

This type of modifications includes the modification of the nucleotides at the 3’-overhangs and the 5’-ends of the duplex. These modifications could be used for the solution of different problems: i) to increase the nuclease resistance of siRNA towards exoribonucleases (inverted 3’-3’ or 5’-5’ deoxyriboses [61, 121](fig. 8), dideoxycytosine [122], ENA-analog of the thymidine [74]etc.), ii) to facilitate asymmetric RISC* assembly (the replacement of the 5’-OH by 5’-OMe group in the terminal nucleoside [123]) and ii) to provide the efficient accumulation of siRNA in cells (attachment of lipophilic molecules [57, 124, 125], folic acid [126], peptides [14, 127, 128], aptamers [129]). The fluorescent residues [111] and biotin [130] are widely used as a termini modification for siRNA detection.

The type of the applicable terminal modification has to be selected experimentally. In many cases the modification of the 5’- and 3’-ends of the sense (“passenger”) strand is well tolerated [59, 131, 111, 130], however the data on modification of the antisense (“guide”) strand are discrepant. It is known that the phosphorylation of 5’-OH groups of the antisense strands of synthetic siRNAs by the kinases [33, 122] is essential for interaction with PIWI-domain of Ago2 and for correct selection of the “guide” strand [29, 30, 31]. Therefore the replacement of the 5’-OH group by the 5’-OMe in the sense strand blocks its phosphorylation and the incorporation into RISC* as a “guide” strand [123]. On the other hand, the same modification of the antisense strand resulted in the decrease of siRNA silencing activity [59, 131, 122]. However, the attachment of the fluorescein residue to the 5’-phosphate of the antisense strand via hexamethylene linker is well tolerated [111], suggesting that this modification does not prevent the interactions of the 5’-terminal phosphate of siRNA with PIWI-domain. The 3’-end of the antisense strand recognized by PAZ-domains of Dicer and Ago2 [21] is less sensitive to modification [14, 33, 59]. It was shown that the attachment of puromycin or biotin to the 3’-end of the antisense strand [130] or the replacement of the 3’-terminal ribonucleotide by ddC, or the attachment of the aminopropyl linker via phosphodiester bond [122] virtually does not change the silencing activity. However, the introduction of the 2-hydroxyethylphosphate, ENA-analog of thymidine [74] or fluorescent dyes [111] at the 3’-end of the antisense strand abolished the silencing. The replacement of the terminal nucleotides of siRNA in both strands by 5’-5’- or 3’-3’-dioxyribose (fig. 8) results in the increase of the nuclease resistance and does not reduce the silencing activity [59, 61].

Figure 8.

Inverted deoxyribose applied for the protection of 5’- or 3’-termini of siRNA.

3.2.1. Bioconjugates

Anionic siRNA cannot effectively pass through the electrostatic and hydrophobic barriers of the cellular membrane to enter the cytoplasm and to induce RNAi. Conjugation of siRNAs with the lipophilic molecules (cholesterol, derivatives of the oleic, lithocholic and lauric acids), peptides, antibodies, aptamers and other compounds is an effective tool to overcome this problem [132, 133]. The cholesterol was suggested as the first candidate for conjugation, since the natural mechanisms of cholesterol transport exist in mammalian organisms. Apolipoprotein B (ApoB) expressed in the liver and intestine cells is involved in the assembly and secretion of the lipid-protein particles known as very-low-density lipoproteins (VLDL) and low-density lipoproteins (LDL) and in the transport and metabolism of the cholesterol. Since ApoB located on the cellular surface is specific to LDL-receptors, responsible for the delivery of the lipoproteins into cell [132, 134], it was suggested that LDL-receptors could deliver the cholesterol-conjugated siRNAs inside the cells via receptor-mediated endocytosis. It was proved experimentally that LDL-receptors bind with the LDL-particles preliminary associated with cholesterol-conjugated siRNA or the conjugate of siRNA and the oleic or lithocholic acids, however the mechanism of their penetration into cell is not well-defined [125] (Table 1). Moreover, the involvement of the transmembrane protein SID-1 in the transport of the lipophilic conjugates was also shown [135]. It was suggested that SID-1 facilitates the dsRNA penetration into cells forming the channels for diffusion or mediating the interactions with other proteins [125, 135]. The successful use of the cholesterol and the derivatives of lithocholic, oleic and lauric acids for siRNA modification was demonstrated in vitro[124] and in vivo[57] (Table 1). The conjugate of siRNA and cholesterol, attached to the 5’-end of the sense strand, is able to penetrate into the human liver cells in the absence of the transfection agents. siRNA bearing cholesterol in the sense strand inhibits ß-Galgene expression more effectively than siRNAs with the cholesterol in the antisense strand or in the both strands. In the presence of the transfection agent the activity of the unmodified siRNA was comparable with that of the conjugates [124]. The accumulation of siRNA-Chol was detected in liver, heart, kidneys, fatty and pulmonary tissues after intravenous injection of the radioactively labeled conjugates (containing cholesterol at the 3’-end of the sense strand) in mice. It should be noted that cells of these organs express LDL-receptors at high level. Other examples of cholesterol-modified siRNAs with high penetration ability are presented in the Table 1.

Table 1.

Bioconjugates of siRNAs

The conjugation of siRNAs with the peptides could also improve their cellular accumulation (Table 1). 11 amino acid cationic peptide derived from cell-permeable Tat protein and responsible for its nuclear localization was used in a number of studies [14, 127]. It was found that the attachment of this peptide (TAT-peptide) with additional cysteine to the 3’-end of the antisense strand of siRNA results in its effective accumulation in HeLa cells and effective silencing of the target genes EGFPand CDK9[14]. The endocytosis was suggested to be the mechanism of the conjugates penetration into cells [136, 137].

The addition of the cell penetrating peptides (transportan and penetrantin) to the 5’-end of the sense strand of siRNA improves the penetration ability and the silencing activity of anti-EGFPand anti-GL2siRNAs in COS-7, C166-GFP, EOMA-GFP and CHO-AA8-LucTet-Off cells [128] (Table 1). It was suggested that penetration of the conjugates does not occur via pino- or endocytosis, but is mediated by diffusion through plasma membrane [128]. Besides the increase of transfection efficacy, the attachment of the peptides to siRNAs may enhance their specificity. Bioconjugates of siRNAs with peptides inhibiting the RISC assembly and containing specific sequence cleavable by cell-specific peptidases are promising agents for cell-specific gene silencing [138]. The efficient inhibition of the exogenous GFPexpression was observed in choriocarcinoma Jeg-3 cells after electroporation of the conjugate of siRNA and a peptide with the “LEVD” sequence recognized by caspase-4, whereas in caspase-4 deficient HEK 293 cells the conjugate was inactive [138].

Another approach to the enhancement of siRNA cellular accumulation is the delivery of siRNA conjugated with antibodies or aptamers [132]. The aptamers are structured synthetic nucleic acids with size less than 15 kDa (Table 1), they can be chemically modified for the defense from the nucleases [139]. The penetration of these conjugates occurs via specific interactions with receptors on the surface of the target cells, providing the effective cellular accumulation of siRNAs [132]. The conjugates of anti-BCL2or anti-PLK1(polo-like kinase 1) siRNA and PSMA-receptor specific aptamer, effectively penetrate into prostate cancer LNCaP cells and induce effective gene silencing [129]. Injection of these conjugates into tumor expressing PSMA-receptors results in tumor regression [140]. It was shown also that the conjugates of siRNA and anti-transferrin or anti-insulin monoclonal antibodies attached to siRNA via streptavidin-biotin linker effectively reduces the exogenous F.luciferaseexpression in HEK 293 cells and rat glial cells implanted in the brain [141, 142] (Table 1).

The attachment of the folic acid to siRNA is a promising approach to increasing cellular uptake of siRNA. These conjugates can penetrate into virtually all human cancer cells, since expression of the expression of the folate receptors on the surface of the cancer cells is substantially higher than in normal cells [143]. The efficient accumulation of fluorescein-labeled siRNA with folate attached to the 5’- or 3’-end of the sense strand via disulfide bond was observed in solid tumor in mice [126] (Table 1). In the other studies [144, 145]the delivery of siRNA into cells was performed with folate-containing structures. These experiments (in vivoand in vitro) verified the advantage of siRNA modification by folate: specific delivery into cancer cells and high silencing effect of these siRNAs was observed.

The introduction of biomolecules in siRNA is one of the promising approaches of non-viral delivery. In contrast to other non-viral methods (cationic lipids and polymers, high-pressure injections) the advantages of conjugation include the cell-specificity and the absence of toxic effect [63, 146, 147, 148, 149]. The employment of cholesterol- and folate-contaning siRNAs in vivois less specific, since LDL- and folate-receptors are expressed by different cells [125, 150], however, this approach is could be usefully applied when strict cell or tissue selectivity is not required.

3.3. Combination of chemical modifications

The application of different modifications simultaneously is a widely-used approach for the optimization of siRNA properties. Two main strategies are considered in order to increase nuclease resistance of siRNA. The first one is based on the extensive modification of siRNA. In this case optimal design of the duplex (i.e. selection of modifications) could be created experimentally by the analysis of the data on nuclease resistance and biological activity. For example, different types of modifications were used in totally modified siRNA, displaying high activity in mice infected with Hepatitis B virus. The sense strand of this siRNA contains deoxyribonucleotides instead of the purine ribonucleotides, 2’-F-modifications and 5’-5’- and 3’-3’-terminal deoxyribonucleotides instead of the pyrimidine bases; the antisense strand contains alternating 2’-F / 2’-O-Me groups; one PO-bond between 3’-terminal nucleotides was replaced by PS-bond [61] (Table 2). Other examples of siRNA containing different combinations of chemical modifications are presented in the table 2. However, the extensive modification of siRNA often is not well-tolerated by RNAi machinery and rather often leads to the reduction or blocking of the silencing activity [40, 59, 99]. Therefore, minimization of the number of modifications in siRNA structure is required. It was shown, that duplexes with limited number of LNA-modifications could be active and as resistant to nucleases as the totally modified 2’-O-Me / 2’-F-siRNAs, which were inactive [40, 59, 99, 99] (Table 2). Since siRNAs are degraded mainly by endoribonucleases [59], it was suggested that the increase of the thermostability will increase the nuclease resistance [99]. On the other hand, it is known that the pattern of siRNA degradation in the presence of serum is similar to the cleavage by RNase A [62]. Therefore, the selective modification of the nuclease sensitive sites of siRNAs, mapped in the presence of serum, represents an alternative approach to the extensive modification of siRNA. This rational approach of siRNA modification allows to minimize the number of modified nucleotides in the duplex and as a consequence, to maintain its silencing activity [76]. The optimization of siRNA design also includes the defense of the 3’-terminal nucleotides against exonuclease cleavage (see section 1.2.2).

The combinations of chemical modifications are used for optimization of other siRNA properties. In order to achieve in vivoboth the efficient cellular uptake and their high nuclease resistance, the 2’-O-Me-modified or/and PS-modified siRNAs conjugated with cholesterol were used [57, 151]. In order to increase the thermoasymmetry of the duplex, the nucleotide analogs with opposite effect on the siRNA thermostability can be used simultaneously. For instance, LNA- and UNA-analogs introduced in siRNA simultaneously was shown to enhance the silencing activity of the siRNA due to the increase of thermoasymmetry of the duplex: duplex stabilization of the duplex by LNA-analogs at the 5’-end and destabilization by UNA-analogs at the 3’-end of the sense strand [99].

The increase of the RNAi efficacy was also observed after stabilization of the 3’-end of the antisense strand of siRNA by s2U or ψ analogs and destabilization of the 5’-end by introduction of D at the 3’-end of the sense strand [120]. It should be noted that the decrease of the thermostability of the duplex at the 3’-end of the sense strand is more preferable in comparison with the stabilization of the duplex at the 5’-end of the sense strand if the duplex stabilization is not needed [99].

Thus, in order to optimize siRNA design by chemical modifications the following principles should be considered: modifications should provide 1) the RNA-like A-helix geometry of the duplex; 2) the access of the terminal 5’-OH group of the antisense strand for phosphorylation; 3) low thermostability of the 5’-end of the antisense strand, hence, the modification has to increase the favorable thermoasymmetry or has no effect on the duplex thermostability.

Table 2.

Extensive and selective modification of siRNA

Table 3.

Influence of the chemical modifications on siRNA properties

The information on the influence of chemical modifications on siRNA properties is summarized in the table 3.


4. The impact of the siRNA structure on the efficiency of RNAi

The investigation of the structures of natural siRNAs formed by dsRNA processing with Dicer and endogenous miRNA revealed the common siRNA structures. "Classical" small interfering RNA resembles duplexes 18 - 23 bp in length [18, 22, 156, 157] with 2 nt overhangs at 3'-ends [40, 45] (fig. 9).

However, it was clearly demonstrated, that the silencing activity of structurally similar duplexes with different sequences varies significantly. As it was mentioned above thermodynamic asymmetry of the duplex and to a lesser extend the structure of mRNA target determines the siRNA activity [44, 45, 57, 58, 60]. Possibility to optimize the duplex structure was demonstrated in a number of publications. Introduction of nucleotide substitutions in siRNA, resulting in a formation of non-canonical base pairs or mismatches [38, 158, 159] is a perspective approach for the optimization of the thermodynamic properties of the duplex. The other approach utilize the inactivation of the sense strand of siRNA (for example, segmentation) to guarantee the incorporation of the antisense strand into activated RISC* independent from the thermodynamic properties of the duplex [99]. The silencing activity of siRNA can be increased by the lengthening of the duplex and converting siRNA into Dicer substrate DsiRNA [160, 161] or by the modifications of the overhands affecting duplex thermodynamic asymmetry [162]. Single stranded analogs of siRNA can be also used as inducers of RNAi, in this case the problem of the strand selection does not exist [40, 77]. All mentioned approaches will be described in details below.

Figure 9.

Structural repertoire of siRNA. The triangle indicates single stranded nick.

4.1. The influence of nucleotide substitutions on the silencing activity of siRNA

Thermodynamic properties of siRNA play a key role on the stages of RISC activation and mRNA target cleavage, determining the efficiency of strand dissociation, strand selection and mRNA cleavage. Since that, nucleotide substitutions affecting thermodynamic stability of the duplex could change the silencing activity of siRNA. The nature of the changes depends on the type of substitutions and the location of the substitutions in siRNA structure. The data on the impact of nucleotide substitutions in the silencing activities of siRNAs reported in the literature are summarized in Table 4.

The kinetics of mRNA cleavage directed by anti-F.luciferase and anti-sod1siRNA, containing nucleotide substitutions in one of the strands of the duplex were exanimated in details in [38]. It was shown, that the substitution of cytosine with uracil at the 5’-end of the sense strand of anti-F.luciferasesiRNA, resulting in U:G pair formation (stabilized by two hydrogen bonds)[163]), reduced the target mRNA cleavage rate. At the same time, the rate of the antisense RNA (complementary to the first target) cleavage increased substantially. The analysis of the binding of siRNA strands with RISC* revealed, that single nucleotide substitution at the position 1 of the sense strand reduce the incorporation of the antisense strand in the complex, whereas the efficiency of the sense strand incorporation into RISC* increased (fig. 10 A).

Nucleotide substitution at the 3’-end of the sense strand of anti-sod1siRNA resulting in the formation of А:G mismatch (fig. 10 B), caused the opposite effect: the rate of mRNA cleavage increased, while the rate of antisense mRNA cleavage decreased. This result indicates that the efficiency of the sense strand incorporation into RISC* decreases. The observed effect could be caused both by preferential incorporation of the antisense strand into RISC complex, and by non-perfect complementarity between the sense strand of siRNA and its target (antisense mRNA), but the results of the additional experiments with the substitution of G by C at the 5’-end of the antisense strand (fig. 10 B) verified the key role of preferential RISC loading [38]. Thus, it was clearly demonstrated, that single nucleotide substitutions at the flank regions of siRNA could change the thermodynamic asymmetry and to determine the preferential incorporation of one strand into RISC*: destabilization of the duplex at the 3’-end of the sense strand increase the activity of siRNA, the destabilization of the opposite end of the duplex, reduce the silencing activity [38].

Figure 10.

The scheme of the experiment described in 38. А. Substitution at the 5’-end of the sense strand of anti-F.luciferasesiРНК. B. Substitution at the 3’-end of the sense strand (left) or at the 5’-end of the antisense strand (right) of anti-sod1siRNA.

Table 4.

The influence of the nucleotide substitutions in siRNA on the efficiency of RNAi

The elevation of the thermodynamic asymmetry by single nucleotide substitution at the 1th position of the antisense strand was reported to increase or have no influence on the silencing activity of different siRNAs, targeted to sod1 / F.luciferasemRNA or the complementary sequence (antisense mRNA) [164] (Table 4). In turn, the equal efficiency of the cleavage of httmRNA and httantisense mRNA by thermodynamically symmetrical siRNA suggests the equal probability of sense or antisense strand incorporation into RISC* [38].

Introduction of the nucleotide substitutions at the 3’-end of the sense strand of siRNA duplex resulted in the formation of the mismatches, has led to the creation of the structurally new class of small interfering RNAs – fork-like siRNAs (fsiRNAs) [158]. More effective silencing of the expression of R.luciferase/P.luciferasegene by fsiRNAs then by classical siRNA targeted to the same sequences was demonstrated in Hela cells (Table 4). The most pronounced augmentation of the activity was observed for siRNA with initially moderate activity [158]. Fork-like siRNA with two nucleotide substitutions at the 3’-end of the sense strand was found to be the most active [11, 158, 159] (Table 4). Introduction of from 2 to 4 nucleotide substitutions at the 3’-end of the sense strand of siRNA targeted sod1and httmRNAa correspondingly increased the efficiency of silencing[38].

The increase of the thermodynamic asymmetry of the duplex by the introduction of the mismatches at the ends of the strands cannot guarantee the positive influence on the activity. It is known, that the region of the “guide” strand spanning from 2 to 6 position determines the efficiency of the interaction of siRNA with Ago2 [21, 30, 31]; this fact limits the introduction of substitutions in this region. Nevertheless, С→U substitution in 2d position of the antisense strand of siRNA targeted Jagged-1mRNA increased the silencing effect from 0 to 50% in НЕК 293Т cells transfected with vector, containing cDNA fragment of the target gene [165] (Table 4). This data suggests, that the substitutions in the antisense strand resulted in the formation of non-canonical base pairs is more tolerable than the substitutions resulted in the formation of mismatches. In the other study, single nucleotide substitutions at 19th position of the sense strand or at the 1st position of the antisense strand resulting in the formation of the mismatches as well as non-canonical base-pairs reduced the activity of anti-EGFPsiRNA in H1299 cells. It was assumed that the reduction of the efficiency of the interaction of TRBP (but not the Dicer) with siRNA was the possible reason of the observed effect [24] (Table 4).

Introduction of nucleotide substitutions in the central part of siRNA duplex could be used for the destabilization the central region and the subsequent elevation of the silencing activity. Nevertheless, this type of structure modification could switch the mode of siRNA action to miRNA-like mechanism [167] (fig. 4). It was demonstrated in experiments on HeLa cells, that substitutions in 9th and 10th positions of the sense strand of siRNA leads to the 2 - 4.5-fold increase of IC50 as compared with IC50 for siRNA with classical duplex 36. Substitutions in the sense strand or in both strands of siRNA [167] reduced the efficiency of RNAi (Table 4).

Thus, the introduction of nucleotide substitutions could be successfully used for the design of siRNA characterized by favorable thermodynamic asymmetry and low thermostability of the central part of the duplex. This approach can be applied for the creation active siRNA targeted to any desired sequence for silencing of mutated or chimerical genes. However, there is not enough data publish up to date for the formulation of the universal rules for the design of fork-like siRNA and siRNA with destabilized center, the activity of resulted siRNA cannot be predicted and should be determined experimentally.

4.2. The influence of the siRNA overhangs structure on the efficiency of gene silencing

2 - 3 nt overhangs at the 3’-ends of siRNA are a distinguishing feature of both natural siRNA generated by Dicer and synthetic siRNA [40, 45, 162]. The overhangs are important for the interaction of siRNA with PAZ-domens of Dicer and Ago2 [21, 27, 168]. However, the data on the activity of siRNA with blunt ends (with no overhangs) are rather contradictory: in mammalian cells the activity of this type of siRNA did not vary significantly from the activity of siRNA with 2-nt overhangs targeted to the same sequence [59], controversially, in extracts from drosophila cells blunt ends siRNA were less active [40, 45]. The assumption that observed difference could be accounted for the difference in the mechanism of action of heterodimer Dicer-R2D2 in drosophila and its analogue Dicer-TRBP in humans [59], did not find the experimental support, since it was reported recently, that in HeLa S3 the activity of the blunt ended siRNA was similarly lower (60% silencing) than the activity of classical siRNA (80 % silencing) [162]. Moreover, the presence of 2 nt overhang at the 3’-end of only one of the strands leads to the selection of this strand as a guide strand due to the preferential loading into RISC*[162]. The presence of the mismatches at the 5’-end of the antisense strand resulting in the formation of thermodynamically asymmetrical duplex increases the efficiency of the incorporation of antisense strand, containing 2 nt overhang, into RISC*. Efficient silencing of the target gene expression by fork-like structurally asymmetrical siRNA was achieved in a number of studies conducted on HeLa cells (Table 4, 2nd type of siRNA).

It was found the 1 nt shortening of the overhang (1 ntoverhang instead of 2) at the 3’ end in some cases did not affect significantly the silencing activity [40]. The sequential lengthening of the 3’-end overhang in the sense or the antisense strand up to 7 nt induced the substantial reduction of the silencing activity of siRNA [40], probably due to inefficient interaction of this siRNAs with PAZ-domen of Dicer [29]. siRNAs, containing overhangs at the 5’-ends of the duplex were inactive in RNAi [40], and induced side effects related to the PKR-mediated activation of the innate immunity [169].

Therefore, exploitation of the structurally asymmetrical siRNAs, containing 2 nt overhang only at the 3’-end of the antisense strand together with the reduction of the thermodynamic stability of the duplex at the 5’-end region of the antisense strand could be successfully used in siRNA design for increasing the efficiency of RNAi.

4.3. Single stranded analogous of siRNA (ss-siRNA)

Before the discovery of RNAi, it was demonstrated that long (several hundred bases in length) single stranded RNA are capable of sequence specific silencing of the expression of homologous genes in C.elegans[170]. Later, it was assumed that the minor fraction of dsRNA in the preparations of ssRNA obtained by in vitrotranscription was the agent that silence the expression of the target genes 1. However, the ability of antisense, but not sense ssRNA (22 – 40 nt) to induce gene silencing was experimentally verified in C.elegans[171]. It was demonstrated that mRNA degradation induced by ssRNA proceeds via RISC* assembling (fig. 9) [131,122]. The evaluation of the silencing activity of anti-luciferasess-siRNA in HeLa cells demonstrated, that the required concentration of ss-siRNA was 8-fold higher, than the concentration of classical siRNA to reach the similar level of gene silencing. In the other report, it was shown, that the concentration of ss-siRNA essential for the RISC assembling was 10 – 100 higher than the concentration of double stranded siRNA analogous [122]. High sensitivity of single stranded RNA to ribonucleases [62], and less efficient interaction with the RNAi machinery proteins [131,122] were supposed to be the possible reasons of the lower efficiency of RNAi induction by ssRNA.

Thus, the application of non-modified ss-siRNA as inhibitors of gene expression is not beneficial in comparison with double stranded siRNA.

4.4. dsRNA (27-30-mers) as Dicer substrates

During the search of the effective inductors of RNAi, able to silence target gene at low (nanomolar and lower) concentrations, it was found that dsRNAs 25-30 bp in length which are substrates of Dicer (here and after DsiRNA – Dicer-substrate siРНК), are significantly more active in comparison with “classic” or “conventional” siRNAs [161, 172, 173, 174]. To compare interfering activity of DsiRNA and conventional siRNA the duplexes of different length (21-30 bp) and structure (presence or absence of 3’ or 5’ dinucleotide overhangs) targeting EGFPwere used [174]. The interfering activity of dsRNA was evaluated at concentration ranging from 50 pMol to 50 nMol using HEK293 cells transfected with the plasmid encoded EGFP. It was shown that at subnanomolar concentrations (50 pM– 200 pM) DsiRNAs were significantly more active than siRNA. Among duplexes tested the DsiRNA 27 bp in length with blunt ends displays the highest interfering activity: this DsiRNA (1 nM) inhibited expression of the target gene by 95% (Table 5) while corresponding siRNA was almost inactive [174]. It turned out, that this DsiRNA (27 bp, blunt ends) is processed by Dicer yielding pull of different siRNAs 21bp in length. Seven siRNAs (21 bp with 3’-dinucleotide overhangs) generated by single-nucleotide shift along the EGFPmRNA sequence homologous to DsiRNA were synthesized to answer the question can the synthetic siRNA be as active as this particular DsiRNA. It was shown that at the concentrations 50 pM and 200 pM neither each synthetic siRNA nor pull of synthetic siRNAs silence expression of EGFP as efficiently as corresponding DsiRNA. Interestingly, in the case if DsiRNA was processed by Dicer in vitroand then transfected into the cells the silencing efficiency of this processed DsiRNA was similar to the activity of synthetic siRNAs [174]. It has been suggested, than after DsiRNA cleavage Dicer did not dissociated from the complex with DsiRNA and thus governed the mode of interaction of R2D2 (D.melanogaster) or TRBP (H.sapiens) and, as a consequence, the unequivocal orientation of siRNA within the RISC. This provides for incorporation into the RISC the antisense strand of the duplex. However, if an equivocal binding of Dicer with dsRNA takes place which results in a formation of a set of siRNA cleavage products, the possibility of formation of incompetentRISC*, containing sense strand of siRNA as a leading strand is increased. Thus, optimization of a structure of DsiRNA is a current task.

It is known, that one of the functions of Dicer within the cell is a processing of pre-miRNA via binding with their 3’-end, containing two hanging nucleotides followed by cleavage of the duplex at a distance of 21-22 nucleotides from the 3’-end [172]. Taking into account that Dicer has a low affinity to DNA, a set of asymmetric dsRNA was synthesized, containing at the 3’-end of the sense or antisense strand two nucleotides overhang, while the opposite end was blocked for Dicer binding by the replacement of two ribonucleotides in the complementary strand by deoxyribonucleotides [161, 172] (Table 5, structures 25D/27 and 27/25D). It was anticipated that such a structure of DsiRNAs provide for an unequivocal binding of the duplex with Dicer.

According to mass-spectrometry the cleavage of these DsiRNA by Dicer (Table 5, structures 25D/27 and 27/25D) yields the same product in both cases [161]. However, the silencing activity of siRNAs derived from these DsiRNAs was different; which possibly is explained by the peculiarities of DsiRNA interactions with Dicer, determined the efficiency of sense or antisense incorporation into RISC*.

Table 5.

The influence of DsiRNA structure in its silencing activity

It was shown, that in HEK293 and HeLa cells the DsiRNAs with antisense strand having dinucleotide overhang at the 3’-end were more active than those with dinucleotide overhang at the 3’-end of the sense strand (Table 5) [161, 172]. Thus, it is possible to predict the structure of forming siRNAs upon processing of DsiRNA by Dicer [161, 172], however, the activity of these siRNAs will depend on the thermodynamic parameters of their duplexes. It worth mentioning that in the case of unfavorable context of the target sequence within mRNA DsiRNAs have a significant advantage over conventional siRNA [174].

The silencing activity of a longer dsRNAs with blunt ends (27 – 45 bp) decreases with the increase of dsRNA length. It turns out that this drop of silencing activity correlate well with the drop of efficiency of cleavage of longer dsRNAs by Dicer [174]. The silencing effect caused by DsiRNA was longer in comparison with conventional siRNA: DsiRNAs efficiently silence EGFPexpression in NIH3T3 cells for 10 days while corresponding siRNA displays silence activity not longer than 4-7 days [174].

Despite the promising results on silence activity of Dicer substrates the optimization of the properties of DsiRNAs by chemical modification is relevant. The influence of 2’-F- and 2’-O-Mе modifications within DsiRNA type 25D/27 on the silencing activity and nuclease resistance was studied [173]. When choosing sites of modifications authors try to avoid the region needed for Dicer to execute dsRNA cleavage, despite presence there of nuclease sensitive motives (Fig. 11).

Figure 11.

Design of chemically modified DsiRNA. By bold letter N deoxyribonucleotides areshown, short arrows – cleavage site of DsiRNA by Dicer.

It was shown, that chemical modification of DsiRNA affects its silencing activity in respect to STAT1mRNA only at the lowest concentration used (100 pM), while at higher concentration of DsiRNA (1 and 10 nM) the drop of silencing activity was detected only for extensively modified molecules, containing combination of several 2’-F- and 2’-O-Me nucleotides in a row. DsiRNA containing 11 2’-O-Me nucleotides in the antisense strand was very nuclease resistant: the fraction of intact DsiRNA was found in reaction mixture after 24 h of incubation in the presence of serum. However, such an extensive modification affects pattern of DsiRNA cleavage by Dicer and lead to the formation of two products of 21 and 22 bp instead of one product of 21 bp formed with unmodified DsiRNA. Replacement of one or two 2’-O-Me nucleotides in the vicinity of Dicer cleavage sites by the natural ones facilitated formation of 21 bp cleavage product. The introduction from 1 to 4 mismatches into central part of each strand of anti-EGFPDsiRNA significantly reduced its silencing activity [174].

On the other hand, chemical modification of DsiRNA can block induction of the unspecific immune response in mammalian cells, linked with the presence of triphosphate groups at the 5’ ends of DsiRNA or/and immunostimulating motives in the duplex [43,175, 176, 177, 178, 179,180]. So, DsiRNA, which contains in the antisense strand 10 -11 2’-O-Me nucleotides (including 2’-O-Me-cytidine and 2’-O-Me-uridine nucleotides known as the most effective blockers of interferon response activation via endosomal TLR [64]), blocked IFN-α secretion by human PBMC and did not induce immune response in RIG-I-dependent T98G cells opposite to unmodified DsiRNA and 2’-F-modified disРНК, respectively [173].

Full replacement of natural nucleotides by the analogs (2’-O-Me, 2’-F, etc.) is unacceptable as these DsiRNA will not be processed by Dicer [173]. Therefore, upon the introduction of chemical modifications in the structure of DsiRNA one should avoid modifying the nucleotides from 1 to 8 from 5’ end of the sense strand and complementary region of the sense strand (Fig. 11). Moreover, two overhanging nucleotides at the 3’-end of the antisense strand as well as two deoxyribonucleotides at the 3’-end of the sense strand facilitate the correct orientation of Dicer and selection of the antisense strand of DsiRNA as a leading strand.

4.5. Small segmented RNA

Recently another approach to enhance RNAi efficiency based on modification of siRNA structure was proposed [99]. It was shown that siRNA in which the sense strand is subdivided in two parts of 10-12 nucleotides long, are more active in comparison with conventional siRNA duplexes. The efficiency of this internally segmented siRNA or sisiRNA (small internally segmented interfering RNA) (Fig. 9) was provided by unequivocal incorporation of the antisense strand into RISC*, since the nick in the central part of the sense strand blocked its usage as a guiding strand and facilitate the dissociation of the sense strand from the duplex [99]. Thus, sisiRNA have an advantage over conventional siRNA with unfavorable duplex thermoasymmetry. In addition unlike siRNAs with the classic structurethe extensive chemical modification of antisense strand of sisiRNA has only little effect on its silencing activity. As an example, the silencing activity of anti-EGFPsisiRNA with antisensestrand having 6 LNA-nucleotides or alternative 2’-F / 2’-O-Me-nucleotides and internally segmented sense strand with 6 LNA-nucleotides in each part was significantly higher than that of conventional siRNA bearing the same modifications [99]. Besides, both mentioned sisiRNA display high nuclease resistance. Thus, sisiRNAs as sequence specific inhibitors of gene expression are very promising, because they provide efficient RNAi even at the unfavorable thermodynamic parameters RNA duplex.

According to literary data the structural and thermodynamic peculiarities of interfering RNAs are a major factors providing for efficient gene silencing.

Prediction of silencing activity of any siRNA based on its thermodynamic profile is an efficient method of selection of active molecules. This approach is used in a number of software and algorithms for search and selection of such siRNA [37]. An alternative approach to the problem of creating efficient sequence-specific inhibitors of gene expression is the use of structure-modified siRNAs: fork-like siRNAs, DsiRNAs, or sisRNAs which silencing activity is less dependent on their thermodynamic parameters as compared with conventional siRNA diplex.


5. Conclusion

Small interfering RNAs are not optimal to be used as therapeutics in vivo, therefore, development of the approached aimed to improve or/and optimize the properties of siРНК is of significance nowadays. One of the approaches widely used is chemical modification of siRNAs. At the beginning this approach was proposed as a way to increase nuclease resistance of siRNA in the presence of serum, in the cells and bloodstream [61, 62]. The enhancement of nuclease resistance of siRNA by chemical modification not resulting in the drop of its silencing activity represent a complex task, since silencing activity of siRNA is strongly affected by the nature, number and locations within the duplex of chemical modifications [65, 76, 181]. Despite many works carried out in this area, a general algorithm which allows receiving active nuclease resistant siRNA is not developed yet.

Chemical modification of siRNA can be also used to develop delivery vehicles for siRNA. It is well known that naked or free siRNA is not able to penetrate through cellular membrane and accumulate in the cells. In the case of in vivo conditions, the small size of siRNA molecule promotes its rapid clearance [57]. In other words, the systems for in vivo delivery of siRNAs should provide for efficiency of cellular accumulation, specificity of delivery (if applicable), duration of silencing as well as safety and possibility of systemic administration. Today no one delivery approach encounters these criteria.

On the other hand, the low efficiency of RNAi can be a result of its unfavorable sequence determining thermodynamic properties and/or by stable secondary structure at the target site within mRNA [37, 38, 51, 52, 54]. There are several algorithms to select siRNAs of high-performance [182, 183, 184, 185, 186], however it is impossible to predict precisely silencing activity of any particular siRNA in vivo. In addition, the design of siRNA targeting chimeric or mutant genes represent of complex task since the limitations of target site selection does not allow to use these algorithms for choosing the sequence siRNA. This is why structure modifications of siRNA improving their thermodynamic properties are of interest. The fork-like siRNA [158, 159], able to silence target gene more efficiently that conventional siRNA is a promising approach for creating high-performance siRNA targeted any sequence of the gene. Despite this, the number of works in this field is negligible so further research of properties of siRNA with modified structure are relevant.

To obtain high-performance siRNA often optimization of multiple parameters is required, so using modification of the siRNA structure together with its chemical modification is a promising approach. Thus, advanced research of chemically and/or structurally modified siRNA, as well as development and optimization of the algorithms for modification are important.


This research was supported by the Russian Academy ofScience under the programs Molecular and Cell Biology(grant no. 22-1) and Science to Medicine (grant no. 37), the Russian Foundationfor Basic Research (grant nos. 11-04-01017-a and 11-04-12095-ofi-m-2011) Ministry of Science and Education of the Russian Federation (grant no. 14.740.11.1058)and the SiberianBranch of Russian Academy of Sciences (grant no. 85).


  1. 1. FireAXuSMontgomeryM. KKostasS. ADriverS. EandMelloC. C1998Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature.391806811
  2. 2. BosherJ. MandLabouesseM2000RNA interference: genetic wand and genetic watchdog. Nat Cell Biol. 2, E3136
  3. 3. SharpP. A1999RNAi and double-strand RNA. Genes Dev.13139141
  4. 4. VaucheretHandFagardM2001Transcriptional gene silencing in plants: targets, inducers and regulators. Trends Genet.172935
  5. 5. HammondS. MBernsteinEBeachDandHannonG. J2000An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature.404293296
  6. 6. AignerA2006Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. J Biotechnol.1241225
  7. 7. AroninN2006Target selectivity in mRNA silencing. Gene Ther.13509516
  8. 8. HannonG. J2002RNA interference. Nature.418244251
  9. 9. HutvagnerG2005Small RNA asymmetry in RNAi: function in RISC assembly and gene regulation. FEBS Lett.57958505857
  10. 10. RanaT. M2007Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol.82336
  11. 11. HohjohH2002RNA interference (RNA(i)) induction with various types of synthetic oligonucleotide duplexes in cultured human cells. FEBS Lett.521195199
  12. 12. MancheLGreenS. RSchmedtCandMathewsM. B1992Interactions between double-stranded RNA regulators and the protein kinase DAI. Mol Cell Biol.1252385248
  13. 13. ElbashirS. MHarborthJLendeckelWYalcinAWeberKandTuschlT2001Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature.411494498
  14. 14. ChiuY. LAliAChuC. YCaoHandRanaT. M2004Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol.1111651175
  15. 15. ElbashirS. MHarborthJWeberKandTuschlT2002Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods.26199213
  16. 16. PaddisonP. JCaudyA. AandHannonG. J2002Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci U S A.9914431448
  17. 17. PreallJ. BandSontheimerE. J2005RNAi: RISC gets loaded. Cell.123543545
  18. 18. ZamoreP. DTuschlTSharpP. AandBartelD. P2000RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell.1012533
  19. 19. ChendrimadaT. PGregoryR. IKumaraswamyENormanJCoochNNishikuraKandShiekhattarR2005TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature.436740744
  20. 20. TomariYMatrangaCHaleyBMartinezNandZamoreP. D2004A protein sensor for siRNA asymmetry. Science.30613771380
  21. 21. MaJ. BYeKandPatelD. J2004Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain. Nature.429318322
  22. 22. ZhangHKolbF. ABrondaniVBillyEandFilipowiczW2002Human Dicer preferentially cleaves dsRNAs at their termini without a requirement for ATP. Embo J.2158755885
  23. 23. GrunwellerAandHartmannR. K2005RNA interference as a gene-specific approach for molecular medicine. Curr Med Chem.1231433161
  24. 24. KiniH. KandWaltonS. P2009Effect of siRNA terminal mismatches on TRBP and Dicer binding and silencing efficacy. FEBS J.27665766585
  25. 25. LiuXJiangFKalidasSSmithDandLiuQ2006Dicer-2andRD2 coordinately bind siRNA to promote assembly of the siRISC complexes. Rna.1215141520
  26. 26. HutvagnerGandSimardM. J2008Argonaute proteins: key players in RNA silencing. Nat Rev Mol Cell Biol.92232
  27. 27. SongJ. JSmithS. KHannonG. JandJoshua-torL2004Crystal structure of Argonaute and its implications for RISC slicer activity. Science.30514341437
  28. 28. BernsteinECaudyA. AHammondS. MandHannonG. J2001Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature.409363366
  29. 29. MaJ. BYuanY. RMeisterGPeiYTuschlTandPatelD. J2005Structural basis for 5’-end-specific recognition of guide RNA by the A. fulgidus Piwi protein. Nature.434666670
  30. 30. ParkerJ. SRoeS. MandBarfordD2005Structural insights into mRNA recognition from a PIWI domain-siRNA guide complex. Nature.434663666
  31. 31. RivasF. VToliaN. HSongJ. JAragonJ. PLiuJHannonG. JandJoshua-torL2005Purified Argonaute2 and an siRNA form recombinant human RISC. Nat Struct Mol Biol.12340349
  32. 32. MeisterGandTuschlT2004Mechanisms of gene silencing by double-stranded RNA. Nature.431343349
  33. 33. NykanenAHaleyBandZamoreP. D2001ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell.107309321
  34. 34. LeuschnerP. JAmeresS. LKuengSandMartinezJ2006Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO Rep.7314320
  35. 35. MatrangaCTomariYShinCBartelD. PandZamoreP. D2005Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell.123607620
  36. 36. AddepalliHMeena, Peng C. G., Wang G., Fan Y., Charisse K., Jayaprakash K. N., Rajeev K. G., Pandey R. K., Lavine G., Zhang L., Jahn-Hofmann K., Hadwiger P., Manoharan M. and Maier M. A. (2010Modulation of thermal stability can enhance the potency of siRNA. Nucleic Acids Res.3873207331
  37. 37. KhvorovaAReynoldsAandJayasenaS. D2003Functional siRNAs and miRNAs exhibit strand bias. Cell.115209216
  38. 38. SchwarzD. SHutvagnerGDuTXuZAroninNandZamoreP. D2003Asymmetry in the assembly of the RNAi enzyme complex. Cell.115199208
  39. 39. HaleyBandZamoreP. D2004Kinetic analysis of the RNAi enzyme complex. Nat Struct Mol Biol.11599606
  40. 40. ElbashirS. MMartinezJPatkaniowskaALendeckelWandTuschlT2001Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. Embo J.2068776888
  41. 41. LiuJCarmellM. ARivasF. VMarsdenC. GThomsonJ. MSongJ. JHammondS. MJoshua-torLandHannonG. J2004Argonaute2 is the catalytic engine of mammalian RNAi. Science.30514371441
  42. 42. BraaschD. AandCoreyD. R2002Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry.4145034510
  43. 43. DorsettYandTuschlT2004siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov.3318329
  44. 44. BertrandJ. RPottierMVekrisAOpolonPMaksimenkoAandMalvyC2002Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun.29610001004
  45. 45. ElbashirS. MLendeckelWandTuschlT2001RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev.15188200
  46. 46. PrakashT. PAllersonC. RDandePVickersT. ASioufiNJarresRBakerB. FSwayzeE. EGriffeyR. HandBhatB2005Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J Med Chem.4842474253
  47. 47. ChuC. YandRanaT. M2006Translation repression in human cells by microRNA-induced gene silencing requires RCK/54PLoS Biol. 4, e210.
  48. 48. JakymiwAPauleyK. MLiSIkedaKLianSEystathioyTSatohMFritzlerM. JandChanE. K2007The role of GW/P-bodies in RNA processing and silencing. J Cell Sci.12013171323
  49. 49. ChalkA. MWahlestedtCandSonnhammerE. L2004Improved and automated prediction of effective siRNA. Biochem Biophys Res Commun.319264274
  50. 50. ReynoldsALeakeDBoeseQScaringeSMarshallW. SandKhvorovaA2004Rational siRNA design for RNA interference. Nat Biotechnol.22326330
  51. 51. BrownK. MChuC. YandRanaT. M2005Target accessibility dictates the potency of human RISC. Nat Struct Mol Biol.12469470
  52. 52. GredellJ. ABergerA. KandWaltonS. P2008Impact of target mRNA structure on siRNA silencing efficiency: A large-scale study. Biotechnol Bioeng.100744755
  53. 53. HolenTAmarzguiouiMWiigerM. TBabaieEandPrydzH2002Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. Nucleic Acids Res.3017571766
  54. 54. WesterhoutE. MandBerkhoutB2007A systematic analysis of the effect of target RNA structure on RNA interference. Nucleic Acids Res.3543224330
  55. 55. AmarzguiouiMBredeGBabaieEGrotliMSproatBandPrydzH2000Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes. Nucleic Acids Res.2841134124
  56. 56. BraaschD. AParooZConstantinescuARenGOzO. KMasonR. PandCoreyD. R2004Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett.1411391143
  57. 57. SoutschekJAkincABramlageBCharisseKConstienRDonoghueMElbashirSGeickAHadwigerPHarborthJJohnMKesavanVLavineGPandeyR. KRacieTRajeevK. GRohlIToudjarskaIWangGWuschkoSBumcrotDKotelianskyVLimmerSManoharanMandVornlocherH. P2004Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature.432173178
  58. 58. ChiuY. LandRanaT. M2003siRNA function in RNAi: a chemical modification analysis. Rna.910341048
  59. 59. CzaudernaFFechtnerMDamesSAygunHKlippelAPronkG. JGieseKandKaufmannJ2003Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res.3127052716
  60. 60. HaupenthalJBaehrCKiermayerSZeuzemSandPiiperA2006Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum. Biochem Pharmacol.71702710
  61. 61. MorrisseyD. VBlanchardKShawLJensenKLockridgeJ. ADickinsonBMcswiggenJ. AVargeeseCBowmanKShafferC. SPoliskyB. AandZinnenS2005Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology.4113491356
  62. 62. TurnerJ. JJonesS. WMoschosS. ALindsayM. AandGaitM. J2007MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Mol Biosyst.34350
  63. 63. WhiteP. J2008Barriers to successful delivery of short interfering RNA after systemic administration. Clin Exp Pharmacol Physiol.3513711376
  64. 64. JudgeA. DBolaGLeeA. Cand MacLachlan I. (2006Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther.13494505
  65. 65. ManoharanM2004RNA interference and chemically modified small interfering RNAs. Curr Opin Chem Biol.8570579
  66. 66. RobbinsMJudgeALiangLMcclintockKYaworskiEand MacLachlan I. (2007O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther.1516631669
  67. 67. JudgeAand MacLachlan I. (2008Overcoming the innate immune response to small interfering RNA. Hum Gene Ther.19111124
  68. 68. TakedaKandAkiraS2005Toll-like receptors in innate immunity. Int Immunol.17114
  69. 69. Zamanian-daryoushMMarquesJ. TGantierM. PBehlkeM. AJohnMRaymanPFinkeJandWilliamsB. R2008Determinants of cytokine induction by small interfering RNA in human peripheral blood mononuclear cells. J Interferon Cytokine Res.28221233
  70. 70. KleinmanM. EYamadaKTakedaAChandrasekaranVNozakiMBaffiJ. ZAlbuquerqueR. JYamasakiSItayaMPanYAppukuttanBGibbsDYangZKarikoKAmbatiB. KWilgusT. ADiPietro L. A., Sakurai E., Zhang K., Smith J. R., Taylor E. W. and Ambati J. (2008Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature.452591597
  71. 71. BraaschD. AJensenSLiuYKaurKArarKWhiteM. AandCoreyD. R2003RNA interference in mammalian cells by chemically-modified RNA. Biochemistry.4279677975
  72. 72. ChoungSKimY. JKimSParkH. OandChoiY. C2006Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun.342919927
  73. 73. KraynackB. AandBakerB. F2006Small interfering RNAs containing full 2’-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity. RNA.12163176
  74. 74. HamadaMOhtsukaTKawaidaRKoizumiMMoritaKFurukawaHImanishiTMiyagishiMandTairaK2002Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3’-ends of siRNAs. Antisense Nucleic Acid Drug Dev.12301309
  75. 75. ParrishSFleenorJXuSMelloCandFireA2000Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference. Mol Cell.610771087
  76. 76. WattsJ. KDeleaveyG. FandDamhaM. J2008Chemically modified siRNA: tools and applications. Drug Discov Today.13842855
  77. 77. AllersonC. RSioufiNJarresRPrakashT. PNaikNBerdejaAWandersLGriffeyR. HSwayzeE. EandBhatB2005Fully 2’-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem.48901904
  78. 78. LayzerJ. MMccaffreyA. PTannerA. KHuangZKayM. AandSullengerB. A2004In vivo activity of nuclease-resistant siRNAs. RNA.10766771
  79. 79. MuhonenPTennilaTAzhayevaEParthasarathyR. NJanckilaA. JVaananenH. KAzhayevAandLaitala-leinonenT2007RNA interference tolerates 2’-fluoro modifications at the Argonaute2 cleavage site. Chem Biodivers.4858873
  80. 80. IkedaHFernandezRWilkABarchiJ. JJr., Huang X. and Marquez V. E. (1998The effect of two antipodal fluorine-induced sugar puckers on the conformation and stability of the Dickerson-Drew dodecamer duplex [d(CGCGAATTCGCG)]2. Nucleic Acids Res.2622372244
  81. 81. DamhaM. JNoronhaA. MWildsC. JTrempeJ. FDenisovAPonR. TandGehringK2001Properties of arabinonucleic acids (ANA & 20’F-ANA): implications for the design of antisense therapeutics that invoke RNase H cleavage of RNA. Nucleosides Nucleotides Nucleic Acids.20429440
  82. 82. Ui-teiKNaitoYZennoSNishiKYamatoKTakahashiFJuniAandSaigoK2008Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res.3621362151
  83. 83. AmarzguiouiMHolenTBabaieEandPrydzH2003Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res.31589595
  84. 84. DornGPatelSWotherspoonGHemmings-mieszczakMBarclayJNattF. JMartinPBevanSFoxAGanjuPWishartWandHallJ2004siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 32, e49.
  85. 85. ChenXShenLandWangJ. H2004Poly-2’-DNP-RNAs with enhanced efficacy for inhibiting cancer cell growth. Oligonucleotides.149099
  86. 86. LiaoHandWangJ. H2005Biomembrane-permeable and Ribonuclease-resistant siRNA with enhanced activity. Oligonucleotides.15196205
  87. 87. AshunM. AHuYKangILiC. CandWangJ. H1996Inhibition of murine leukemia virus with poly-2’-O-(24dinitrophenyl)poly[A]. Antimicrob Agents Chemother. 40, 2311-2317.
  88. 88. BramsenJ. BLaursenM. BNielsenA. FHansenT. BBusCLangkjaerNBabuB. RHojlandTAbramovMVan AerschotAOdadzicDSmiciusRHaasJAndreeCBarmanJWenskaMSrivastavaPZhouCHoncharenkoDHessSMullerEBobkovG. VMikhailovS. NFavaEMeyerT. FChattopadhyayaJZerialMEngelsJ. WHerdewijnPWengelJandKjemsJ2009ALarge-scalechemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res.3728672881
  89. 89. De MesmaekerAAltmannK. HWaldnerAandWendebornS1995Backbone modifications in oligonucleotides and peptide nucleic acid systems. Curr Opin Struct Biol.5343355
  90. 90. InoueHHayaseYImuraAIwaiSMiuraKandOhtsukaE1987Synthesis and hybridization studies on two complementary nona(2’-O-methyl)ribonucleotides. Nucleic Acids Res.1561316148
  91. 91. DandePPrakashT. PSioufiNGausHJarresRBerdejaASwayzeE. EGriffeyR. HandBhatB2006Improving RNA interference in mammalian cells by 4’-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2’-O-alkyl modifications. J Med Chem.4916241634
  92. 92. HoshikaSMinakawaNKamiyaHHarashimaHandMatsudaA2005RNA interference induced by siRNAs modified with 4’-thioribonucleosides in cultured mammalian cells. FEBS Lett.57931153118
  93. 93. HoshikaSMinakawaNShionoyaAImadaKOgawaNandMatsudaA2007Study of modification pattern-RNAi activity relationships by using siRNAs modified with 4’-thioribonucleosides. Chembiochem.821332138
  94. 94. BraaschD. AandCoreyD. R2001Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem Biol.817
  95. 95. GrunwellerAWyszkoEBieberBJahnelRErdmannV. AandKurreckJ2003Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2’-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res.3131853193
  96. 96. ElmenJThonbergHLjungbergKFriedenMWestergaardMXuYWahrenBLiangZOrumHKochTandWahlestedtC2005Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res.33439447
  97. 97. HornungVGuenthner-billerMBourquinCAblasserASchleeMUematsuSNoronhaAManoharanMAkiraSDe FougerollesAEndresSandHartmannG2005Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med.11263270
  98. 98. MookO. RBaasFDe WisselM. BandFluiterK2007Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol Cancer Ther.6833843
  99. 99. BramsenJ. BLaursenM. BDamgaardC. KLenaS. WBabuB. RWengelJandKjemsJ2007Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res.3558865897
  100. 100. HerdewijnPAllartBDe BouvereBDe WinterHHendrixCHossainNSchepersGVerheggenIWroblowskiBandVan AerschotA1999Properties of oligonucleotides with six membered base moiety and the hydroxymethyl group mimics and a14relationship between the base moiety and the hydroxymethyl group. Nucleosides & Nucleotides. 18, 1371-1376.
  101. 101. KozlovI. AZielinskiMAllartBKerremansLVan AerschotABussonRHerdewijnPandOrgelL. E2000Nonenzymatic template-directed reactions on altritol oligomers, preorganized analogues of oligonucleotides. Chemistry.6151155
  102. 102. HerdewijnPAllartBDe BouvereBDe WinterHHendrixCHossainNSchepersGVerheggenIWroblowskiBandVan AerschotA1999Properties of oligonucleotides with six membered base moiety and the hydroxymethyl group mimics and a14relationship between the base moiety and the hydroxymethyl group. Nucleosides & Nucleotides. 18, 1371-1376.
  103. 103. FisherMAbramovMVan AerschotAXuDJulianoR. LandHerdewijnP2007Inhibition of MDR1 expression with altritol-modified siRNAs. Nucleic Acids Res.3510641074
  104. 104. KenskiD. MCooperA. JLiJ. JWillinghamA. THaringsmaH. JYoungT. AKuklinN. AJonesJ. JCancillaM. TMcmastersD. RMathurMSachsA. BandFlanaganW. M2010Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5’-terminal phosphorylation both in vitro and in vivo. Nucleic Acids Res.38660671
  105. 105. LangkjaerNPasternakAandWengelJ2009UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability. Bioorg Med Chem.1754205425
  106. 106. KenskiD. MCooperA. JLiJ. JWillinghamA. THaringsmaH. JYoungT. AKuklinN. AJonesJ. JCancillaM. TMcmastersD. RMathurMSachsA. BandFlanaganW. M2010Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5’-terminal phosphorylation both in vitro and in vivo. Nucleic Acids Res.38660671
  107. 107. WerkDWengelJWengelS. LGrunertH. PZeichhardtHandKurreckJ2010Application of small interfering RNAs modified by unlocked nucleic acid (UNA) to inhibit the heart-pathogenic coxsackievirus B3. FEBS Lett.584591598
  108. 108. BrownS. CThomsonS. AVealJ. MandDavisD. G1994NMR solution structure of a peptide nucleic acid complexed with RNA. Science.265777780
  109. 109. DemidovV. VPotamanV. NFrank-kamenetskiiM. DEgholmMBuchardOSonnichsenS. HandNielsenP. E1994Stability of peptide nucleic acids in human serum and cellular extracts. Biochem Pharmacol.4813101313
  110. 110. PotenzaNMoggioLMilanoGSalvatoreVDi Blasio B., Russo A. and Messere A. (2008RNA interference in mammalia cells by RNA-3’-PNA chimeras. Int J Mol Sci.9299315
  111. 111. HarborthJElbashirS. MVandenburghKManningaHScaringeS. AWeberKandTuschlT2003Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev.1383105
  112. 112. HallA. HWanJShaughnessyE. ERamsay Shaw B. and Alexander K. A. (2004RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res.3259916000
  113. 113. SchwarzD. STomariYandZamoreP. D2004The RNA-induced silencing complex is a Mg2+-dependent endonuclease. Curr Biol.14787791
  114. 114. LeeMSimonA. DSteinC. AandRabbaniL. E1999Antisense strategies to inhibit restenosis. Antisense Nucleic Acid Drug Dev.9487492
  115. 115. PrakashT. PKraynackBBakerB. FSwayzeE. EandBhatB2006RNA interference by 2’,5’-linked nucleic acid duplexes in mammalian cells. Bioorg Med Chem Lett.1632383240
  116. 116. IwaseRToyamaTandNishimoriK2007Solid-phase synthesis of modified RNAs containing amide-linked oligoribonucleosides at their 3’-end and their application to siRNA. Nucleosides Nucleotides Nucleic Acids.2614511454
  117. 117. SaengerW1984Forces stabilizing association between bases: Hydrogen bonding and base stacking. In Principle of nucleic acids structure. Springer-Verlag, New York.
  118. 118. AgrisP. FSierzputowska-graczHSmithWMalkiewiczASochackaEandNawrotB1992Thiolation of uridine carbon-2 restricts the motional dynamics of the transfer RNA wobble position nucleoside. J. Am. Chem. Soc.11426522656
  119. 119. DavisD. RVeltriC. AandNielsenL1998An RNA model system for investigation of pseudouridine stabilization of the codon-anticodon interaction in tRNALys, tRNAHis and tRNATyr. J Biomol Struct Dyn.1511211132
  120. 120. SipaKSochackaEKazmierczak-baranskaJMaszewskaMJanickaMNowakGandNawrotB2007Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA. RNA.1313011316
  121. 121. MorrisseyD. VLockridgeJ. AShawLBlanchardKJensenKBreenWHartsoughKMachemerLRadkaSJadhavVVaishNZinnenSVargeeseCBowmanKShafferC. SJeffsL. BJudgeAMacLachlan I. and Polisky B. (2005Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol.2310021007
  122. 122. SchwarzD. SHutvagnerGHaleyBandZamoreP. D2002Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol Cell.10537548
  123. 123. ChenP. YWeinmannLGaidatzisDPeiYZavolanMTuschlTandMeisterG2008Strand-specific 5’-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA.14263274
  124. 124. LorenzCHadwigerPJohnMVornlocherH. PandUnverzagtC2004Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett.1449754977
  125. 125. WolfrumCShiSJayaprakashK. NJayaramanMWangGPandeyR. KRajeevK. GNakayamaTCharriseKNdungoE. MZimmermannTKotelianskyVManoharanMandStoffelM2007Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol.2511491157
  126. 126. ThomasMKularatneS. AQiLKleindlPLeamonC. PHansenM. JandLowP. S2009Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues. Ann N Y Acad Sci.11753239
  127. 127. MoschosS. AJonesS. WPerryM. MWilliamsA. EErjefaltJ. STurnerJ. JBarnesP. JSproatB. SGaitM. JandLindsayM. A2007Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem.1814501459
  128. 128. MuratovskaAandEcclesM. R2004Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett.5586368
  129. 129. McnamaraJ. Ond, Andrechek E. R., Wang Y., Viles K. D., Rempel R. E., Gilboa E., Sullenger B. A. and Giangrande P. H. (2006Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol.2410051015
  130. 130. ChiuY. LandRanaT. M2002RNAi in human cells: basic structural and functional features of small interfering RNA. Mol Cell.10549561
  131. 131. MartinezJPatkaniowskaAUrlaubHLuhrmannRandTuschlT2002Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell.110563574
  132. 132. De PaulaDBentleyM. VandMahatoR. I2007Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. Rna.13431456
  133. 133. GaglioneMandMessereA2010Recent progress in chemically modified siRNAs. Mini Rev Med Chem.10578595
  134. 134. BurnettJ. RandBarrettP. H2002Apolipoprotein B metabolism: tracer kinetics, models, and metabolic studies. Crit Rev Clin Lab Sci.3989137
  135. 135. FeinbergE. HandHunterC. P2003Transport of dsRNA into cells by the transmembrane protein SID-1. Science.30115451547
  136. 136. PotockyT. BMenonA. KandGellmanS. H2003Cytoplasmic and nuclear delivery of a TAT-derived peptide and a beta-peptide after endocytic uptake into HeLa cells. J Biol Chem.2785018850194
  137. 137. RichardJ. PMelikovKVivesERamosCVerbeureBGaitM. JChernomordikL. VandLebleuB2003Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem.278585590
  138. 138. PoehlmannT. GRuedigerTSchaeferHKoehnSImhofDSeyfarthLSchubertU. SandMarkertU. R2009Development of small interfering RNA selectively activated in target cells. In RNAi2009: ncRNA: Bridging Biology and Therapy (Media L. P., ed.)^eds.).1617Library Publishing Media, Oxford, UK.
  139. 139. HickeB. JandStephensA. W2000Escort aptamers: a delivery service for diagnosis and therapy. J Clin Invest.106923928
  140. 140. DassieJ. PLiuX. YThomasG. SWhitakerR. MThielK. WStockdaleK. RMeyerholzD. KMccaffreyA. PMcnamaraJ. Ond and Giangrande P. H. (2009Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol.27839849
  141. 141. XiaC. FBoadoR. JandPardridgeW. M2009Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. Mol Pharm.6747751
  142. 142. XiaC. FZhangYBoadoR. JandPardridgeW. M2007Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res.2423092316
  143. 143. XiaWandLowP. SFolate-targeted therapies for cancer. (2010J Med Chem.5368116824
  144. 144. KimS. HMokHJeongJ. HKimS. WandParkT. G2006Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. Bioconjug Chem.17241244
  145. 145. ZhangKWangQXieYMorGSegaELowP. SandHuangY2008Receptor-mediated delivery of siRNAs by tethered nucleic acid base-paired interactions. RNA.14577583
  146. 146. JeongJ. HMokHOhY. KandParkT. G2009siRNA conjugate delivery systems. Bioconjug Chem.20514
  147. 147. KawakamiSandHashidaM2007Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab Pharmacokinet.22142151
  148. 148. LengQWoodleM. CLuP. YandMixsonA. J2009Advances in Systemic siRNA Delivery. Drugs Future. 34, 721.
  149. 149. LvHZhangSWangBCuiSandYanJ2006Toxicity of cationic lipids and cationic polymers in gene d Xia W. and Low P. S. Folate-targeted therapies for cancer. (2010) J Med Chem.5368116824elivery. J Control Release. 114, 100-109.
  150. 150. De FougerollesAVornlocherH. PMaraganoreJandLiebermanJ2007Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov.6443453
  151. 151. WuYNavarroFLalABasarEPandeyR. KManoharanMFengYLeeS. JLiebermanJandPalliserD2009Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe.58494
  152. 152. BlidnerR. AHammerR. PLopezM. JRobinsonS. OandMonroeW. T2007Fully 2’-deoxy-2’-fluoro substituted nucleic acids induce RNA interference in mammalian cell culture. Chem Biol Drug Des.70113122
  153. 153. CoreyD. R2007Chemical modification: the key to clinical application of RNA interference? J Clin Invest.11736153622
  154. 154. JeongJ. HMokHOhY. KandParkT. G2009siRNA conjugate delivery systems. Bioconjug Chem.20514
  155. 155. JacksonA. LBurchardJLeakeDReynoldsASchelterJGuoJJohnsonJ. MLimLKarpilowJNicholsKMarshallWKhvorovaAandLinsleyP. S2006Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA.1211971205
  156. 156. MacraeI. JZhouKLiFRepicABrooksA. NCandeW. ZAdamsP. DandDoudnaJ. A2006Structural basis for double-stranded RNA processing by Dicer. Science.311195198
  157. 157. MyersJ. WJonesJ. TMeyerTandFerrellJ. EJr. (2003Recombinant Dicer efficiently converts large dsRNAs into siRNAs suitable for gene silencing. Nat Biotechnol.21324328
  158. 158. HohjohH2004Enhancement of RNAi activity by improved siRNA duplexes. FEBS Lett.557193198
  159. 159. OhnishiYTokunagaKandHohjohH2005Influence of assembly of siRNA elements into RNA-induced silencing complex by вилко-siRNA duplex carrying nucleotide mismatches at the 3’- or 5’-end of the sense-stranded siRNA element. Biochem Biophys Res Commun.329516521
  160. 160. KuboTZhelevZOhbaHandBakalovaR2007Modified 27-nt dsRNAs with dramatically enhanced stability in serum and long-term RNAi activity. Oligonucleotides.17445464
  161. 161. RoseS. DKimD. HAmarzguiouiMHeidelJ. DCollingwoodM. ADavisM. ERossiJ. JandBehlkeM. A2005Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res.3341404156
  162. 162. SanoMSierantMMiyagishiMNakanishiMTakagiYandSutouS2008Effect of asymmetric terminal structures of short RNA duplexes on the RNA interference activity and strand selection. Nucleic Acids Res.3658125821
  163. 163. MasquidaBandWesthofE2000On the wobble GoU and related pairs. RNA.6915
  164. 164. DingHLiaoGWangHandZhouY2007Asymmetrically designed siRNAs and shRNAs enhance the strand specificity and efficacy in RNAi. J RNAi Gene Silencing.4269280
  165. 165. PatzelVRutzSDietrichIKoberleCScheffoldAandKaufmannS. H2005Design of siRNAs producing unstructured guide-RNAs results in improved RNA interference efficiency. Nat Biotechnol.2314401444
  166. 166. HuXHipolitoSLynnRAbrahamVRamosSandWong-staalF2004Relative gene-silencing efficiencies of small interfering RNAs targeting sense and antisense transcripts from the same genetic locus. Nucleic Acids Res.3246094617
  167. 167. PatzelV2007In silico selection of active siRNA. Drug Discov Today.12139148
  168. 168. LingelASimonBIzaurraldeEandSattlerM2004Nucleic acid 3’-end recognition by the Argonaute2 PAZ domain. Nat Struct Mol Biol.11576577
  169. 169. MarquesJ. TDevosseTWangDZamanian-daryoushMSerbinowskiPHartmannRFujitaTBehlkeM. AandWilliamsB. R2006A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat Biotechnol.24559565
  170. 170. GuoSandKemphuesK. J1995par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell.81611620
  171. 171. TijstermanMKettingR. FOkiharaK. LSijenTandPlasterkR. H2002RNA helicase MUT-14-dependent gene silencing triggered in C. elegans by short antisense RNAs. Science.295694697
  172. 172. AmarzguiouiMRossiJ. JandKimD2005Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett.57959745981
  173. 173. CollingwoodM. ARoseS. DHuangLHillierCAmarzguiouiMWiigerM. TSoiferH. SRossiJ. JandBehlkeM. A2008Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides.18187200
  174. 174. KimD. HBehlkeM. ARoseS. DChangM. SChoiSandRossiJ. J2005Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol.23222226
  175. 175. ReynoldsAAndersonE. MVermeulenAFedorovYRobinsonKLeakeDKarpilowJMarshallW. SandKhvorovaA2006Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA.12988993
  176. 176. BridgeA. JPebernardSDucrauxANicoulazA. LandIggoR2003Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet.34263264
  177. 177. PersengievS. PZhuXandGreenM. R2004Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). Rna.101218
  178. 178. SledzC. AHolkoMDe VeerM. JSilvermanR. HandWilliamsB. R2003Activation of the interferon system by short-interfering RNAs. Nat Cell Biol.5834839
  179. 179. HornungVEllegastJKimSBrzozkaKJungAKatoHPoeckHAkiraSConzelmannK. KSchleeMEndresSandHartmannG2006Triphosphate RNA is the ligand for RIG-I. Science.314994997
  180. 180. JudgeA. DSoodVShawJ. RFangDMcclintockKand MacLachlan I. (2005Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol.23457462
  181. 181. ShuklaSSumariaC. SandPradeepkumarP. I2010Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook. ChemMedChem.5328349
  182. 182. AmarzguiouiMandPrydzH2004An algorithm for selection of functional siRNA sequences. Biochem Biophys Res Commun.31610501058
  183. 183. MatveevaONechipurenkoYRossiLMooreBSaetromPOgurtsovA. YAtkinsJ. FandShabalinaS. A2007Comparison of approaches for rational siRNA design leading to a new efficient and transparent method. Nucleic Acids Res. 35, e63.
  184. 184. ShabalinaS. ASpiridonovA. NandOgurtsovA. Y2006Computational models with thermodynamic and composition features improve siRNA design. BMC Bioinformatics. 7, 65.
  185. 185. Ui-teiKNaitoYTakahashiFHaraguchiTOhki-hamazakiHJuniAUedaRandSaigoK2004Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res.32936948
  186. 186. WaltonS. PWuMGredellJ. AandChanC2010Designing highly active siRNAs for therapeutic applications. FEBS J.27748064813

Written By

Natalya S. Petrova, Marina A. Zenkova and Elena L. Chernolovskaya

Submitted: December 14th, 2011 Reviewed: October 1st, 2012 Published: January 9th, 2013